Clinical Trials
23 trialsETAPA I
Duke University
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Roswell Park Cancer Institute
A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma
Dana-Farber Cancer Institute
Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme
Stemline Therapeutics, Inc.
Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
Washington University School of Medicine
A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)
University of California, San Francisco
Pembrolizumab + Poly-ICLC in MRP Colon Cancer
Augusta University
PORTER
Parker Institute for Cancer Immunotherapy
Poly-ICLC
Wake Forest University Health Sciences
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
Roswell Park Cancer Institute
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
Ludwig Institute for Cancer Research
Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Ludwig Institute for Cancer Research
NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma
Ludwig Institute for Cancer Research
A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma
National Cancer Institute (NCI)
Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma
University of Pennsylvania
Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC
H. Lee Moffitt Cancer Center and Research Institute
PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment
H. Lee Moffitt Cancer Center and Research Institute
Radiation Therapy and Temozolomide Followed by Temozolomide and Poly ICLC in Treating Patients With Newly Diagnosed GBM
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Poly-ICLC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs
University of Louisville
Safety Study of Adjuvant Vaccine to Treat Melanoma Patients
Icahn School of Medicine at Mount Sinai
Hiltonol
Icahn School of Medicine at Mount Sinai